Company to Host Conference Call and Webcast on
Wednesday, August 9, 2023
LOS
ANGELES, Aug. 2, 2023 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a commercial-stage
biopharmaceutical company focused on developing and commercializing
precision therapies for genetically-defined cancers with
alterations in mTOR pathway genes, today announced that it will
host a conference call and live webcast on Wednesday, August
9, 2023 at 8:30 am ET (5:30
am PT) to report second quarter 2023 financial results and
provide an operational update.
Conference Call Information
Participants may access a live webcast of the call on the
"Investors & News" page of the Aadi
Bioscience website at www.aadibio.com. To participate via
telephone, please register in advance here: Conference Registration
(vevent.com). Upon registration, all telephone participants will
receive a confirmation email detailing how to join the conference
call, including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. A replay of the
conference call and webcast will be archived on the website for at
least 30 days.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for genetically defined cancers to bring
transformational therapies to cancer patients with mTOR pathway
driver alterations. Aadi received FDA approval in November
2021, and in February 2022 commenced commercialization of
FYARRO® for the treatment of adult patients with
locally advanced unresectable or metastatic malignant perivascular
epithelioid cell tumor (PEComa).
Aadi is conducting the PRECISION 1 trial, a Phase 2
tumor-agnostic registration-directed study in patients with mTOR
inhibitor-naïve malignant solid tumors
harboring TSC1 or TSC2 inactivating
alterations. More information on Aadi's development pipeline is
available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-second-quarter-2023-results-and-operational-update-301891484.html
SOURCE Aadi Bioscience